BayCare Earns National Recognition for Workplace Well-Being
'We are honored that BayCare has been recognized as a national leader and pioneer in promoting well-being and resilience,' said Trish Shucoski, DNP, MSN, RN, NEA-BC, BayCare's chief nurse executive. 'This award is an exciting way to demonstrate that our team members feel supported, valued and equipped to thrive.'
BayCare is one of five organizations nationally to receive the new credential. The Well-Being Excellence™ designation evaluates and enhances well-being programs within health care organizations and other settings that employ nurses, using an evidence-based framework to evaluate:
ANCC created the new designation in response to the urgent need for effective well-being programs to support health care professionals. Nurse burnout is a significant issue in health care, with 46% of health care workers reporting feelings of burnout in 2022, up from 32% in 2018, according to a study by the Centers for Disease Control and Prevention (CDC).
'This prestigious national recognition is a symbol to our patients, our community and our industry that we are deeply committed to the health and well-being of our team members,' said Nikki Daily, BayCare's chief team resources officer.
To receive the 2025 ANCC Well-Being Excellence credential, BayCare submitted a detailed application outlining the ways it currently supports team member well-being, including:
'I am truly encouraged to note the leadership of these pioneering organizations in obtaining this innovative credential. Workplace well-being is critical in improving the overall health of the nation's workforce,' said ANCC President Laura J. Wood, DNP, RN, NEA-BC, FAAN. 'Organizational cultures contribute to both team effectiveness and personal well-being. I look forward to seeing more organizations eager to pursue this qualification given its evidence-based framework and aim to cultivate a culture of well-being within a given workplace and throughout extended communities.'
This recognition joins a growing list of honors BayCare has received locally and nationally for its workplace culture, reinforcing its reputation as a leading not-for-profit health care system and an employer of choice across West Central Florida. BayCare is proud to be the forefront of a nationally accredited effort to set new standards for workforce well-being, helping shape the future of well-being excellence in health care and beyond.
Learn more: Careers at BayCare
About BayCare
BayCare is a leading not-for-profit health care system that connects individuals and families to a wide range of services at 16 hospitals and hundreds of other convenient locations throughout the Tampa Bay and central Florida regions. The system is West Central Florida's largest provider of behavioral health and pediatric services and its provider group, BayCare Medical Group, is one of the largest in the region. BayCare's diverse network of ambulatory services includes laboratories, imaging, surgical centers, BayCare Urgent Care locations, wellness centers and one of Florida's largest home care agencies, BayCare HomeCare. BayCare's mission is to improve the health of all it serves through community-owned, health care services that set the standard for high-quality, compassionate care. For more information, visit BayCare.org.
View original content to download multimedia: https://www.prnewswire.com/news-releases/baycare-earns-national-recognition-for-workplace-well-being-302445071.html
SOURCE BayCare Health System
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Human Microbiome Market worth $7.09 billion by 2031 with 31.0% CAGR
DELRAY BEACH, Fla., Aug. 20, 2025 /PRNewswire/ -- The global Human Microbiome Market, valued at US$0.91 billion in 2024, stood at US$1.40 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of US$7.09 billion by the end of the period. The primary drivers behind the expansion of this industry are the technological advancement in microbiome sequencing, the collaborative efforts between the microbiome industry, organizations, and academia for microbiome research, and the increase in the number of startups and SMEs exploring the microbiome niche, and further opportunities such as the increase in demand for personalized medicine and the emergence of synbiotics may help drive the human microbiome market. Download PDF Brochure: Browse in-depth TOC on "Human Microbiome Market" 416 - Tables64 - Figures371 - Pages By type, bacterial consortia transplantation (BCT)/ fecal microbiota transplantation (FMT), live bacteria products, and others segment the human microbiome market. Live bacteria products accounted for the largest share of the human microbiome market in 2024. This category includes probiotics and synbiotics, which are widely used in consumer health supplements and emerging therapeutic applications. The dominance of live bacteria products is driven by strong consumer demand for digestive and immune health solutions, along with increasing clinical validation of specific bacterial strains. These products are often easier to formulate, regulate, and distribute compared to more complex microbiome therapies, allowing for faster commercialization. Additionally, ongoing advancements in encapsulation and delivery technologies have improved bacterial stability and survivability through the gastrointestinal tract, enhancing their effectiveness. The growing focus on personalized nutrition and preventive health has further expanded the adoption of live bacteria products across various age groups and health segments. Fecal microbiota transplantation/biological combination therapies (FMT/BCT) accounted for the second-largest share, supported by approved drugs such as VOWST and Rebyota for recurrent Clostridioides difficile infection. By end users, the human microbiome market is segmented by end users, hospitals & clinics, long-term care facilities, and other end users. Hospitals and clinics accounted for the largest share of the human microbiome market in 2024. This is largely due to their critical role in administering, monitoring, and regulating microbiome-based therapeutics, particularly those targeting infectious and gastrointestinal conditions. Approved products such as VOWST and Rebyota, used to prevent recurrent Clostridioides difficile infection, are typically prescribed and delivered in clinical settings under medical supervision. These facilities provide the necessary infrastructure for managing live microbial therapies, which may require cold-chain storage, specialized handling, and follow-up care. Hospitals and clinics are also key sites for clinical research, including patient enrollment for microbiome-based drug trials and real-world evidence studies. Their involvement enables close monitoring of patient outcomes, adverse events, and long-term therapeutic effects, all of which are essential for the advancement of microbiome science and regulatory approval processes. Moreover, the rising prevalence of chronic conditions linked to microbiome imbalance, such as inflammatory bowel disease and metabolic disorders, has led to increased hospital-based consultations and treatment protocols involving microbiome interventions. The presence of trained healthcare professionals, diagnostic tools, and institutional trust further supports the strong uptake of microbiome products within hospital and clinical environments. By geography, in 2024, North America accounted for the largest share of the human microbiome market. This leading position is supported by a well-established biotechnology ecosystem, strong research and development infrastructure, and the presence of major market players such as Seres Therapeutics, Seed Health, and IFF. The region has seen significant regulatory progress, with the US FDA approving the first microbiome-based drugs, including Rebyota and VOWST, for the prevention of recurrent Clostridioides difficile infection. These approvals have encouraged further investment in microbiome therapeutics and supplements. North America also has high adoption rates for probiotics, prebiotics, and synbiotics, driven by increasing consumer awareness of gut health and preventive wellness. The region supports a growing number of clinical trials and academic collaborations focused on the role of microbiomes in conditions such as gastrointestinal diseases, metabolic disorders, and cancer. Additionally, favorable healthcare spending, innovation funding, and regulatory clarity continue attracting startups and established firms. These combined factors reinforce the dominant position of North America in the global human microbiome market. Request Sample Pages : Some of the leading players in the market include Seres Therapeutics (US), Ferring B.V. (Switzerland), BiomeBank (Australia), Seed Health, Inc. (US), International Flavors & Fragrances Inc. (US), Pendulum (US), Biohm Technologies (US), Actial Farmaceutica Srl (Italy), OptiBiotix Health Plc (UK), resbiotic (US), Infinant Health Inc. (US), BioGaia (Sweden), and ExeGi Pharma (US), among others. Seres Therapeutics (US): Seres Therapeutics is one of the emerging players in the human microbiome market. The company's microbiome therapeutics platform significantly reduces the time typically required to advance therapeutics to the clinic and, ultimately, to the market. The company focuses on R&D to launch advanced products in the market. Its R&D expenses were USD 64.6 million for the year ending December 31, 2024. It specializes in creating oral live biotherapeutic products with defined bacterial consortia intended to modulate the human microbiome. Its lead product, VOWST (formerly SER-109), received FDA approval in April 2023 to prevent recurrent Clostridioides difficile infection. VOWST is the first FDA-approved orally administered microbiome therapeutic. In 2023, Seres Therapeutics implemented organizational changes, including workforce reductions and a narrowed R&D focus. In June 2024, the company entered into an agreement with Nestlé Health Science to transfer full commercialization rights for VOWST. The company continues to pursue clinical development of its remaining programs and maintains collaborations with academic and industry partners. FERRING B.V. (SWITZERLAND) Ferring Pharmaceuticals is a biopharmaceutical company involved in the development of microbiome-based therapeutics. The company operates in multiple therapeutic areas, including reproductive medicine, maternal health, gastroenterology, and urology. Ferring engages in internal research and external partnerships in the microbiome space. It acquired Rebiotix, a company developing live biotherapeutic products targeting the human microbiome. The company developed Rebyota, a fecal microbiota-based therapeutic indicated for preventing recurrent Clostridioides difficile infection. The product received FDA approval in November 2022 and is administered via enema. It has also collaborated with organizations such as Karolinska Institutet, Intralytix, MyBiotics, and PharmaBiome to explore live microbial consortia, bacteriophage-based therapies, and microbiome diagnostics. The company maintains manufacturing and R&D operations in various regions and continues to advance its microbiome programs across therapeutic categories through preclinical and clinical development stages. International Flavors & Fragrances Inc. (US) International Flavors & Fragrances (IFF) operates in the fields of flavor, fragrance, nutrition, and biosciences, with a growing focus on microbiome-based ingredients. The company has developed capabilities in precision fermentation and microbial strain engineering, enabling the industrial-scale production of next-generation probiotics, including strict anaerobes like Akkermansia. These technologies support ingredient development for applications in human and pet health, food, and supplements. IFF's HOWARU brand includes clinically studied probiotic strains such as HN001, HN019, NCFM, Bi-07, and Bl-04. These strains are formulated for specific health outcomes, including immune support, digestive health, stress response, early life development, and healthy aging. HN001 has regulatory recognition in markets like Brazil for reducing eczema risk in infants and pregnant women. IFF offers products such as HOWARU Protect and HOWARU Restore, each targeting different stages of life or health needs. The HOWARU brand includes clinically studied probiotic strains such as HN001, HN019, NCFM, Bi-07, and Bl-04. These strains are formulated for specific health outcomes, including immune support, digestive health, stress response, early life development, and healthy aging. HN001 has regulatory recognition in markets such as Brazil for reducing eczema risk in infants and pregnant women. IFF offers products like HOWARU Protect and HOWARU Restore, each targeting different stages of life or health needs. The microbiome innovation of IFF is supported by ongoing collaborations and a broader portfolio in synthetic biology, enabling the development of functional ingredients across consumer and health product categories. For more information, Inquire Now! Related Reports: Clinical Microbiology Market High Throughput Screening Market Microbiome Sequencing Services Market Rapid Microbiology Testing Market Laboratory Proficiency Testing Market Get access to the latest updates on Human Microbiome Companies and Human Microbiome Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets 登入存取你的投資組合
Business Wire
an hour ago
- Business Wire
Jackson Healthcare Named to PEOPLE Companies That Care List for Second Consecutive Year
ATLANTA--(BUSINESS WIRE)-- Jackson Healthcare ®, one of the nation's premier providers of healthcare workforce services, today announced its second consecutive appearance on the PEOPLE ® Companies that Care list published by PEOPLE and Great Place To Work ®. This distinction highlights and celebrates businesses that lead with care for their people, local communities and the world. 'Being named again to the PEOPLE Companies that Care list is a testament to our deeply rooted company mission and values,' said Shane Jackson, president of Jackson Healthcare. 'One of our core values, Others First, guides us in putting people at the center of everything we do. We prioritize caring for our team and empowering them to make a meaningful impact through their work.' 'This recognition also reflects our deep commitment to providing a hand up in the communities in which we live, work and serve,' added Jackson. 'Through our LoveLifts community impact platform, we partner with over 450 nonprofit organizations worldwide to improve access to healthcare and enhance the wellbeing of young people. This recognition from PEOPLE and Great Place To Work honors the passion and purpose of our people within our organization and beyond, and I could not be more proud.' 'Businesses are vital pillars in the communities where they operate,' stated Michael C. Bush, CEO of Great Place To Work ®. 'Caring for your people and your community isn't something you do after you build a successful business; it's how to make your business successful.' The PEOPLE Companies that Care list is compiled using data from the Great Place To Work Trust Index ™ Survey, which measures whether all employees have a consistently positive experience at work, regardless of background or role. Companies that earn this recognition also submit a narrative with qualitative and quantitative insights to provide a complete picture of how their organizations care for their employees, communities and planet. To be considered for the list, companies must also be Great Place To Work ® Certified ™. 'Witnessing the innovative spirit with which these companies invest in their employees, communities and the world is truly invigorating,' added Charlotte Triggs, PEOPLE GM and editor-in-chief. 'Their commitment reflects our mission, to feature what happens when ordinary people do extraordinary work.' In addition to being on the 2025 PEOPLE Companies that Care list, Jackson Healthcare is on the 2025 Fortune 100 Best Companies to Work For ® list, as well as it's most recent Best Workplaces for Women ™ and Best Workplaces in Health Care ™ lists. The organization has also been Great Place To Work Certified for nearly a decade. About the PEOPLE Companies That Care List Great Place To Work selected the 2025 PEOPLE Companies that Care list by gathering and analyzing over 1.3 million confidential survey responses from companies representing more than 8.4 million U.S. employees at Great Place To Work Certified organizations. Of those, more than 1 million responses came from employees at companies eligible for the list, and these rankings are based on that feedback. Company rankings are derived from 60 employee experience questions within the Great Place To Work Trust Index ™ Survey and essays submitted by participating companies. Read the full methodology. About PEOPLE Launched in 1974, PEOPLE revolutionized personality journalism by celebrating the extraordinary in ordinary people and the ordinary in extraordinary people. Over 50 years later, it remains a trusted authority on human interest and celebrity news, reaching over 100 million consumers through digital platforms, video, social media, the PEOPLE app and print. Renowned for iconic issues such as Sexiest Man Alive and World's Most Beautiful, PEOPLE delivers breaking entertainment news, exclusive red carpet access, and in-depth reporting on today's most compelling newsmakers. With a legacy of award-winning journalism and photojournalism, PEOPLE, a brand of People Inc., is ranked No. 1 in the entertainment news category by Comscore. About Great Place To Work As the global authority on workplace culture, Great Place To Work brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Its proprietary platform and Great Place To Work Model ™ help companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified or receiving recognition on a coveted Best Workplaces ™ List. Follow Great Place To Work on LinkedIn, Twitter, and Instagram, or visit and sign up for the newsletter to learn more. About Jackson Healthcare Jackson Healthcare ® is one of the nation's premier providers of healthcare workforce services and the parent company of more than 20 businesses that share a common mission: to improve the delivery of patient care and the lives of everyone it touches. Powered by expert associates and tens of thousands of clinician providers, it delivers quality care when and where it's needed in communities across the country – helping thousands of health systems, hospitals and medical facilities serve over 20 million patients a year. Jackson Healthcare – which marks its 25 th anniversary in 2025 – is Great Place To Work ® Certified ™ and appears on the latest Forbes list of America's Top Private Companies; Fortune lists of the 100 Best Companies to Work For ® and Best Workplaces in Health Care ™; and PEOPLE ® list of Companies that Care. Learn more at
Business Wire
2 hours ago
- Business Wire
Tivic Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers
FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced it has received, from Statera Biopharma, two investigational new drug applications (INDs) for its lead candidate, Entolimod™. The two INDs cover the use of Entolimod to treat acute radiation syndrome, including both hematopoietic (ARS-H) and gastrointestinal (ARS-GI) sub-syndromes, and the use of Entolimod to treat advanced cancers, including as an anti-tumor agent and for conditions resulting from cancer treatments. 'Transfer of these INDs to Tivic allows us to formally engage the FDA regarding Entolimod's regulatory pathway and enables clinical trials in neutropenia, lymphocyte exhaustion, and other cancer-related conditions,' stated Tivic CEO, Jennifer Ernst. 'While the IND for advanced cancers allows exploration of Entolimod's anti-tumor activity, building on prior developments, we remain focused in the near-term on Entolimod's first indication--acute radiation syndrome.' About Entolimod Entolimod is a novel TLR5 agonist that triggers NF-kB signaling, activating antiapoptotic and cell protective mechanisms. Under the FDA's Animal Rule, Entolimod has been the subject of extensive trials for the treatment of acute radiation syndrome (ARS), and has demonstrated robust survival, enhanced GI tract recovery and improved hematopoiesis in animal models. Entolimod has been granted Fast Track Designation for ARS. Tivic also holds the exclusive rights for Entolimod for the treatment of neutropenia and has the option to license additional indications, including lymphocyte exhaustion, immunosenescence, and chronic radiation syndrome. About Tivic Tivic's dual platform strategy utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late-stage development. Tivic's bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic's approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the FDA and other regulatory authorities; changes to the company's relationship with the its partners; timing and success of clinical trials and study results; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company's business strategy; regulatory requirements and pathways for approval; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 'Risk Factors,' as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
